Table 4 Comparisons of mood among individuals with TSC, as measured by the NDDI-E (German version) questionnaire, according to several potential predictors and assessed using Kruskal–Wallis and Chi-square tests
Predictor | N | Category | Mean | ± SD | 95% CI | p-value* |
|---|---|---|---|---|---|---|
Sociodemographic aspects | ||||||
 Sex | 66 | Male | 12.32 | 4.0 | 11.3–13.3 | 0.767 |
55 | Female | 12.58 | 4.2 | 11.5–13.7 | ||
 Age | 56 | 18–28 y | 11.8 | 4.0 | 10.8–12.9 | 0.192 |
63 | 29–61 y | 13.0 | 4.2 | 11.9–14.0 | ||
 Employment | 49 | Yes | 11.8 | 3.9 | 10.7–12.9 | 0.056 |
34 | No | 13.8 | 4.6 | 12.2–15.9 | ||
 Grade of disability | 38 | 0–80 | 12.5 | 4.1 | 11.2–13.9 | 0.5327 |
57 | 90–100 | 13.2 | 3.6 | 12.2–14.2 | ||
Clinical aspects | ||||||
 Mutation type | 25 | TSC1 | 12.4 | 4.5 | 10.6–14.3 | 0.791 |
31 | TSC2 | 12.3 | 3.6 | 10.9–13.6 | ||
 Active epilepsy | 50 | Yes | 13.2 | 3.8 | 12.2–14.3 | 0.074 |
71 | No | 11.9 | 4.2 | 10.9–12.9 | ||
 Structural brain | 86 | Yes | 13.1 | 4.1 | 12.3–14.0 | 0.004†|
35 | No | 10.7 | 3.5 | 9.5–11.9 | ||
 SEGA | 51 | Yes | 13.1 | 4.2 | 12.0–14.3 | 0.046 |
70 | No | 11.9 | 4.0 | 11.0–12.9 | ||
 Neuropsychiatric | 60 | Yes | 13.7 | 4.0 | 12.6–14.7 | 0.001†|
61 | No | 11.3 | 3.8 | 10.3–12.2 | ||
 AML | 70 | Yes | 12.3 | 4.3 | 11.3–13.4 | 0.866 |
51 | No | 12.6 | 3.8 | 11.5–13.7 | ||
 Lymphangioleiomyomatosis | 12 | Yes | 12.2 | 4.1 | 9.5–14.8 | 0.878 |
109 | No | 12.5 | 4.1 | 11.7–13.3 | ||
 Skin | 116 | Yes | 12.3 | 4.0 | 11.6–13.1 | 0.281 |
5 | No | 14.6 | 5.9 | 7.3–21.9 | ||
 Number of affected organs | 31 | 1–3 | 11.4 | 4.1 | 9.8–12.9 | 0.006†|
73 | 4–6 | 12.3 | 4.0 | 11.4–13.3 | ||
17 | 7–8 | 14.8 | 3.6 | 13.0–16.7 | ||
Therapeutic aspects | ||||||
 Anti-seizure medication polytherapya | 53 | Yes | 12.8 | 3.5 | 11.9–13.8 | 0.487 |
31 | No | 13.6 | 4.1 | 12.0–15.1 | ||
 Everolimus | 51 | Yes | 12.7 | 4.1 | 11.6–13.9 | 0.351 |
70 | No | 12.2 | 4.1 | 11.3–13.2 | ||
 LAEP | 36 | < 35 | 10.0 | 3.7 | 8.7–11.2 | < 0.001†|
84 | ≥35 | 13.6 | 3.7 | 12.8–14.4 | ||